Abstract 2072P
Background
Oral mucositis is a debilitating condition seen in head and neck cancer(HNC) patients treated by radiotherapy(RT). The aim of study was to evaluate the response of combined new oral agents as local applicant to prevent mucositisand to record the change in mucositis grading during and after RT.
Methods
Sixty threepatients of post-operative HNC planned for adjuvantRT were randomized to treat mucositis by soda bicarbonate gargles only (Control arm: n=30) 4-5 times a day or soda bicarbonate gargle along with new agent comprised of five drugs (ORA-5GEL): one tablespoon each of honey, choline salicylate ointment(8.7w/w), and lignocaine ointment(2%w/w), one tablet of fluconazole 150mg and metronidazole 400mg were mixed to form a paste and applied intraorally starting from 2nd week of RT (Study arm:n=33).
Results
Severity of mucositis was found to be either stable or in downgrading trend after the application of the ORA-5 gel. None of the patients had grade3 mucositis in study arm compared to 15 patients in control arm. Grade 1 mucositis was seen in 64% and 97% of patients at the end of week 3 that progressed to grade 2 in 27% and 70% patients study and control arm, respectively, by the end of 4thweek (p<0.001). On univariate analysis, factors associated with higher mucositis grading were: high disease burden (Stage IV), conventional RT technique and concurrent chemotherapy. In study arm reversible trend of grading was observed in this subset of patients also. With the continuous use of soda bicarbonate gargle and symptomatic treatment, the frequency of grade 3 mucositis in control arm decreased, however, there was significant difference in grading in both the groups till week 7(p<0.001). By the end of the treatment, none of the patients in control arm had grade 0 mucositis compared to 73% in study arm.
Conclusions
ORA-5 GEL effectively acts on all stages of mucositis and prevents not only severity and progression in all patients but also shows reversible grading during RT.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
C. Prakash.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2055P - Multidisciplinary Tumor-ICU Board: Enhancing care for critically Ill patients with solid tumors in the ICU
Presenter: Francisco Javier Ros Montana
Session: Poster session 06
2056P - Hospitalization, reconsultations and mortality in the field of oncological emergencies: Who is at higher risk?
Presenter: Eugenia María Martínez Madrid
Session: Poster session 06
2057P - Prevalence of frailty in long-term prostate cancer survivors after radical prostatectomy and its association with quality of life and emotional health
Presenter: Valentin Meissner
Session: Poster session 06
2058P - Reducing waste to improve sustainability and affordability of cancer treatment: Redispensing unused oral anticancer drugs
Presenter: Lisa-Marie Smale
Session: Poster session 06
2059P - The impact of a dental oncology clinic for patients (pts) prescribed bone-modifying agents (BMA) in a cancer centre
Presenter: Harriet Byrne
Session: Poster session 06
2060P - Prevalence and predictor of poor mental adjustment to cancer before lung cancer surgery
Presenter: Junhee Park
Session: Poster session 06
2061P - Network analysis of comprehensive concerns in patients with cancer: Differences between the sexes
Presenter: Kazumasa Yamamoto
Session: Poster session 06
2062P - The psychological distress (PsyD) evaluation in pancreatic cancer (PC) patients (pts): A mono-institutional analysis
Presenter: Maria Bensi
Session: Poster session 06
2063P - Lifestyle changes as cancer treatment: It is time to get specific with our patients
Presenter: Ana Isabel Martin Quesada
Session: Poster session 06
2064P - Hospitalisation of patients with cancer: Identifying points for improvement in patient care in a university hospital in Spain
Presenter: Silvia Roa
Session: Poster session 06